Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of oral deucrictibant for acute hereditary angioedema attacks
NL-OMON60795Phase 3Recruiting
- Sponsor
- Pharvaris
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of deucrictibant in hereditary angioedema (HAE) (2 arms), sponsored by Pharvaris. Primary endpoints: Adverse events, Clinical laboratory tests and 3 more. Started Dec 2022; status: recruiting.
02
Drugs
deucrictibant
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NL-OMON60795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60795.